MDxHealth

MDxHealth is a molecular diagnostics company focused on developing and commercializing advanced epigenetic tests to assist in the detection and treatment of cancer. The company's product portfolio includes ConfirmMDx, a prostate cancer test aimed at addressing false-negative biopsy concerns; SelectMDx, which guides repeat biopsies for prostate cancer; AssureMDx, a noninvasive liquid biopsy test for bladder cancer; and PredictMDx for Glioblastoma, a tissue methylation test that aids in treatment decisions for brain cancer. Established in 2003 and headquartered in Irvine, California, with additional offices in Belgium and the Netherlands, MDxHealth leverages proprietary genomic and epigenetic technologies to provide actionable diagnostic information. The company's revenue is generated through clinical laboratory services and out-licensing of its patented DNA methylation platform and biomarkers, serving markets primarily in the United States and Europe.

Ron Kalfus

CFO

Vishnu Mishra

Associate Director

2 past transactions

Exact Sciences - Oncotype DX GPS Prostate Cancer Business

Acquisition in 2022
Exact Sciences’ Precision Oncology portfolio of genomic tests provide physicians and patients with personalized insights about the patient’s tumor, allowing them to make treatment decisions with a greater degree of confidence.

NovioGendix

Acquisition in 2015
NovioGendix, established in 2008, is a Dutch molecular diagnostics company specializing in non-invasive liquid biopsy tests for prostate cancer. Based in Nijmegen, it offers services such as the PCA3 Test and PROGENSA PCA3 urine test for prostate cancer detection and management. The company also develops molecular diagnostic assays for various urologic cancers, collaborating with Radboud University Medical Center. Its shareholders include BioGeneration Ventures and Participatiemaatschappij Oost Nederland.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.